Strategies for the Production of [11C]LY2795050 for Clinical Use

Org Process Res Dev. 2023 Feb 17;27(2):373-381. doi: 10.1021/acs.oprd.2c00388. Epub 2023 Feb 8.

Abstract

This report describes a comparison of four different routes for the clinical-scale radiosynthesis of the κ-opioid receptor antagonist [11C]LY2795050. Palladium-mediated radiocyanation and radiocarbonylation of an aryl iodide precursor as well as copper-mediated radiocyanation of an aryl iodide and an aryl boronate ester have been investigated. Full automation of all four methods is reported, each of which provides [11C]LY2795050 in sufficient radiochemical yield, molar activity, and radiochemical purity for clinical use. The advantages and disadvantages of each radiosynthesis method are compared and contrasted.

Keywords: carbon-11; late-stage radiolabeling; molecular imaging; opioids; positron emission tomography.